DAYLI Partners

DAYLI Partners Co., Ltd., based in Seoul, South Korea, is a venture capital firm that focuses on early-stage investments in the biotechnology and healthcare sectors. Established in 2014, it operates as both a venture capital arm and an accelerator under the DAYLI Financial Group. The firm seeks to invest in various areas of healthcare, including therapeutics, life sciences, medical devices, and diagnostics. In addition to its focus on early-stage companies, DAYLI Partners also considers secondary investments in companies at the Series A and pre-IPO stages, particularly those expanding internationally. The firm manages several funds specifically targeting the biotech sector, allowing for a diverse range of investments in healthcare innovation.

Jaehwan Cho

Director

Han-Ho Jung

Managing Director

Eun-Seok Lee

Executive Managing Director

In-Ho Kwon Ph.D

Executive Managing Director

Yong-Chul Kim Ph.D

Managing Director

Eun-Young Park Ph.D

Managing Director

60 past transactions

Galux

Venture Round in 2022
Galux provides molecular design technology focusing on discovering and developing novel drugs for incurable and rare diseases using its AI-based drug design platform technologies.

Opticho

Series A in 2022
Opticho develops ultrasound microscopes to aid in preclinical and clinical research. The company focuses on the commercialization of ultrasonic microscopes, which are comprised of an ultrasound diagnostic device and a laser device and are based on optical technology that employs photoacoustic effects to image blood vessels, particularly peripheral blood vessels, allowing researchers to diagnose peripheral vascular diseases.

Pantillogos

Series A in 2021
Pantillogos is a biotech developing next-generation immuno-oncology drugs using immunology, rental and transfer of licenses.

Genedit

Series A in 2021
GenEdit Inc. is a biotechnology company based in Berkeley, California, established in 2016. It specializes in developing innovative genome editing technologies, particularly using the CRISPR/Cas9 system for therapeutic gene editing. The company focuses on addressing the challenges associated with the delivery of gene therapies through its proprietary non-viral nanoparticle-based delivery platform. This platform enables more efficient and accurate delivery of CRISPR components, enhancing the potential for curative treatments for genetic diseases. By systematically screening a library of nanoparticles, GenEdit aims to improve the safety and effectiveness of gene editing, making it a promising solution for a wide range of therapeutic applications.

SeaWith

Series A in 2021
Producer of clean meat intended to prevent raising and slaughtering of livestock from existing livestock settings. The company develops clean meat, which is no different than actual meat, in a laboratory using their own cell culture medium using algae and 3-dimensional structures using seaweed, providing customers with cultured meat that is delicious and affordable.

GI Innovation

Series C in 2021
GI Innovation is a South Korean bio-venture company dedicated to the research and development of innovative biologics, primarily focusing on immuno-oncology and inflammation/immunology diseases. The company leverages its GI-SMART platform technology to enhance the development process of multi-targeting fusion protein therapeutics, aiming for high quality and productivity. By integrating basic science with translational innovation, GI Innovation strives to create new therapeutic options for patients globally, particularly in the areas of immuno-oncology and allergy-related conditions.

Curaum

Series A in 2021
CURAUM Inc. develops and sells oral care and sleep-related health care products in South Korea. The company provides devices Clium Cleaner, a device use for cleaning, sterilization, storage product only for dental oral devices; Clium S-Guard, sensible omnidirectional device for the lower jaw to manage and treat obstructive sleep apnea and snoring; and Clium System, a solution that provides personalized service to manage chronic sleeping disorders through a home health care system. CURAUM Inc. was incorporated in 2017 and is based in Yuseong, South Korea with additional offices in Seoul and Incheon, South Korea; and Newport Beach, California.

RevoSketch

Series B in 2021
RevoSketch is a molecular diagnostics company dedicated to creating innovative digital PCR solutions for the life science industry. It specializes in developing a digital PCR platform that utilizes unique spin partitioning technology, which employs a micro fraction method using centrifugal force. This approach addresses the limitations of existing digital PCR equipment, offering a more straightforward and affordable alternative. By focusing on simplicity and cost-effectiveness, RevoSketch aims to enhance access to reliable molecular diagnostics, providing significant medical benefits to its clients while supporting advancements in life sciences.

Idience

Series A in 2021
Idience a drug development company development and commercialization of innovative new medicines and drive innovation and transform the cancer treatment, also automatically detects and classifies various disorder on multiple imaging modalities, they are using a revolutionary form of artificial intelligence to teach computer to read medical image and automatically provide structured reports.

Vaxcell Bio

Post in 2021
Vaxcell Bio Therapeutics is an pharmaceutical firm that develops anti-cancer drugs, cellular drugs, immune drugs, and other medicines.

PharmCADD

Series A in 2020
Developer of an in-silico drug design platform designed to tackle the demanding challenges across the whole spectrum of the drug discovery process. The company's platform uses protein folding algorithms, artificial intelligence, network theory, quantum calculation and molecular dynamics simulation to circumvent problems arising from conventional rigid protein-ligand docking models, enabling scientists to accelerate the search for a certain or specific drug candidate.

Sugentech

Post in 2020
Sugentech Incorporated is an in-vitro diagnostic company based in Daejeon, South Korea, specializing in personal point-of-care testing and mobile healthcare solutions. Founded in 2011, the company develops innovative diagnostic products utilizing biotechnology, information technology, and nanotechnology. Sugentech offers a wide range of laboratory tests, including immunoblot processors and systems for molecular diagnostics, as well as tests for specific analytes such as C-reactive protein, troponin I, and various antibodies. Additionally, the company provides personal care tests, including digital ovulation and pregnancy tests. Sugentech was previously known as Accugen Healthcare, Inc. and adopted its current name in October 2013.

CSK

Venture Round in 2020
CSK Inc. is a manufacturer of exhaust gas abatement equipment primarily serving the semiconductor and LCD industries across Asia, America, and internationally. Founded in 1997 and based in Yongin, South Korea, the company specializes in products such as plasma and wet scrubbers, thermal and wet scrubbers, and burn and wet combination scrubbers, all designed to purify harmful gases generated during semiconductor manufacturing. In addition to these scrubbers, CSK provides precursor delivery systems for waste gas abatement and offers solutions for exhaust management in the display, solar, and LED markets. The company also engages in research and development activities focused on gas and chemical semiconductor technologies. As of August 2016, CSK operates as a subsidiary of Atlas Copco AB.

Huons

Series C in 2020
Huons is a South Korean company established in 1965, specializing in the manufacturing and sale of high-quality pharmaceutical products. It is recognized for developing the first local anesthetics and plastic ampoule injections in Korea. The company operates through three main divisions: pharmaceuticals, medical devices, and cosmetics. The pharmaceutical division focuses on ethical drugs, while the medical devices division develops products for the safe preparation of blood components. Additionally, Huons offers a range of cosmetic products, including cleansers, creams, and sunscreens. With a strong commitment to quality control and ongoing research and development, Huons exports its products to around 30 countries across North and South America, Europe, Asia, and Africa.

Curiox Biosystems

Series B in 2019
Curiox is a bioinstrumentation company spun out of the Agency for Science, Technology, and Research (A*STAR) in Singapore. Curiox has become a leader in the development and commercialization of innovative assay platforms based on its expertise in surface chemistry and engineering. Curiox’s vision is to accelerate the progress of life sciences, drug discovery and diagnostics through the miniaturization and improved automation of bioassays.

Alodokter

Series C in 2019
Alodokter is a digital health platform that provides an end-to-end digital solution to patients including telemedicine, doctors, and others. It also provides credible information, supportive communities, and in-depth reference material about health subjects that matter to. The platform brings high-quality medical services to its 20 million+ Monthly Active Users by providing an integrated mobile solution for patients and doctors. Alodokter's medical services are fully integrated via an application that can be downloaded on Android and iOS to meet the health needs of the Indonesian public, the latest health content, chat with doctors, an online booking platform for consultation with doctors and/or looking for hospitals. It was founded in 2014 and is based in Jakarta, Indonesia.

Hisense Bio

Series B in 2019
Hisense Bio offers treatment for intractable dental diseases. They provide research on original technology for tooth development and dentin regeneration. They developed physiological dentin regeneration technology and periodontal ligament regeneration technology based on basic dental research . They offer treatment of intractable dental diseases such as tooth decay, dental hypersensitivity, tooth decay, dental caries, and periodontal disease.

Noul

Venture Round in 2019
Noul Co., Ltd. is a South Korean company that specializes in designing and manufacturing blood cell diagnostics equipment. Established in 2015 and headquartered in Yongin-si, the company focuses on addressing chronic and systemic healthcare challenges. Its flagship product, miLab, is a fully automated, all-in-one device that streamlines the diagnostic process by combining sample preparation and AI diagnostics in a single workflow. The miLab platform integrates advanced technologies, including computer vision AI, bioengineering, hardware, and software engineering, to enhance the efficiency and accuracy of blood diagnostics at the point of care.

T&R Biofab

Post in 2019
T&R Biofab Co., Ltd. is a South Korean biotechnology company focused on the research and development of medical devices aimed at transplantation and tissue regeneration. Founded in 2013 and based in Siheung, the company specializes in the manufacturing of bioresorbable scaffolds and offers products such as craniomaxillofacial meshes, dental meshes, and patient-specific implants. Utilizing innovative 3D printing technology, T&R Biofab aims to enhance the regeneration and reconstruction of tissues and organs, contributing to advancements in orthopedics, plastic surgery, and dentistry.

Genomictree

Post in 2019
Genomictree Inc. is a company based out of South Korea.

Jeisys Medical

Post in 2019
Jeisys Medical Inc. designs, develops, and manufactures medical device for plastic surgeons, dermatologist, physicians, and healthcare professionals. The company offers products for treatment areas, such as fat reduction, lifting/tightening, skin rejuvenation, pigmentation treatments, hair removal, tattoo removal, scars and striae distensae, and acne under LIPOcel, ULTRAcel, ULTRAcel Q+ system, INTRAcel PRO, AcGen, Cellec V system, TRI-BEAM Premium, Edge ONE, and SmoothCool brands. It provides its products through a network of distributors in South Korea and internationally. The company was founded in 2001 and is based in Seoul, South Korea.

Genoplan

Series B in 2018
Genoplan Japan, Inc. specializes in personal genetic testing, providing customized products and services that leverage biotechnology and information technology. Based in Fukuoka City, Japan, with an additional office in Korea, the company offers DNA testing kits that analyze users' saliva to deliver tailored lifestyle advice related to diet, fitness, and cosmetics. Utilizing a user-friendly website and smartphone application, Genoplan interprets individual genetic profiles and presents the findings in accessible reports. The company prides itself on its robust research and development laboratories, which employ advanced automated facilities to ensure rapid and accurate DNA analysis. By helping individuals understand their genetic predispositions, Genoplan aims to empower users to make informed decisions about their health and wellness, fostering a more personalized approach to lifestyle management.

SCM Lifescience

Series C in 2018
SCM Lifescience researches and develops medicine and pharmacy. The Company develops high purity allogeneic stem cell therapeutics, proprietary stem cell isolation technology, and other related biological products. SCM Lifescience also produces cosmetics.

Cellid

Venture Round in 2018
Cellid, Inc. is a bioventure company based in Seoul, South Korea, focused on the research and development of immunotherapeutic vaccines for cancer and infectious diseases. The company is advancing several vaccine candidates, including BVAC-C for cervical, head and neck cancers associated with human papilloma virus, BVAC-B for gastric, ovarian, lung, and pancreatic cancers targeting the HER-2/neu antigen, and BVAC-P for prostate and urinary tract cancers utilizing PAP/PSMA antigens. Additionally, Cellid is developing BVAC-M for melanoma and BVAC-Neo, a customized immunotherapeutic vaccine designed from a patient's own cells. Founded in 2006, Cellid aims to create personalized treatment options that leverage the patient's immune system to combat various types of cancer.

Ensol Biosciences

Series C in 2018
Ensol Biosciences Inc. is a biopharmaceutical company based in Daejeon, South Korea, focused on developing innovative therapies for various diseases, including degenerative disc disease, osteoarthritis, cancer, type 1 diabetes, and Alzheimer's dementia. The company's drug pipeline features several candidates, such as Peniel 2000 and Engedi 1000, which are currently in Phase II and Phase I clinical trials, respectively. In addition to human therapeutics, Ensol develops veterinary drugs, including EAD 100 for animal osteoarthritis. The company is also engaged in creating anticancer drugs, with products like Charis 1000 for triple negative breast cancer and Moriah 1000 for Alzheimer's disease. Ensol Biosciences offers contract drug development services, encompassing chemistry, manufacturing, and controls, as well as material synthesis and analysis. Furthermore, it provides a Knowledge-based In Silico Drug Discovery platform and the ETONS system for drug candidate screening. Founded in 2001, the company was previously known as Ensoltek Co., Ltd. before rebranding in 2015.

Mediogen

Series C in 2018
Mediogen Co. Ltd. is a biotechnology company based in Jecheon, South Korea, with an additional office in Seoul. Founded in 2000, the company specializes in the production of health functional food ingredients and finished products, focusing on probiotic formulations containing lactobacillus. Their product range includes various forms such as powder stick packaging, chewable tablets, and hardened capsules. In addition to health foods, Mediogen offers general processed food, fermented herbal medicines, and veterinary medicines, including probiotics tailored for specific species and environmental improvements. The company also develops ingredients for edible cosmetics and high-functional materials. Mediogen leverages patented coating technology to supply raw materials for functional foods, general foods, and cosmetics, promoting overall health and wellness.

3D Medivision

Series B in 2018
3D MediVision, Inc. specializes in the development, manufacturing, and sale of 3D visualization and live-casting systems designed for surgical applications. The company provides a range of products, including 3D/2D cameras, recorders, monitors, and ultrasound systems, which enhance the clarity and immersion of surgical images. Their innovative imaging technology allows for the conversion of traditional ocular views from surgical microscopes into digital 3D-HD visuals, enabling surgeons to capture and share surgical procedures effectively. Additionally, 3D MediVision offers platforms such as SURGFLIX for surgical content sharing and VeterFlix for veterinary training. The company's products are distributed through authorized partners in several countries, including India, Spain, Mexico, and China. Founded in 2011 and headquartered in Seoul, South Korea, 3D MediVision aims to optimize surgical performance through advanced visualization solutions.

42Maru

Debt Financing in 2017
42Maru, Inc., founded in 2015 and based in Seoul, South Korea, specializes in developing advanced search engine technology tailored for artificial intelligence applications. The company has created a deep learning-based question-answering system designed to accurately understand user intent and deliver precise answers. With a focus on various sectors, including connected cars, smart speakers, and chatbots, 42Maru leverages its expertise in information retrieval, machine reading comprehension, and natural language processing to enhance user interactions. The company aims to capitalize on the growing shift from traditional web searches to more intuitive question-answering systems, anticipating significant market growth in the coming years. Its business strategy encompasses B2C initiatives through partnerships with major telecommunications companies in Korea and plans for global expansion with multilingual support. With a strong team led by a seasoned CEO who has over 20 years of experience in the search engine industry, 42Maru is positioned to lead in the rapidly evolving AI landscape.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.